Medpace Holdings, Inc.

  • Market Cap: Small Cap
  • Industry: Miscellaneous
  • ISIN: US58506Q1094
USD
544.77
-38.93 (-6.67%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Medpace Holdings, Inc. stock-summary
stock-summary
Medpace Holdings, Inc.
Miscellaneous
Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.
Company Coordinates stock-summary
Company Details
5375 Medpace Way , CINCINNATI OH : 45227-1543
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 159 Schemes (42.29%)

Foreign Institutions

Held by 250 Foreign Institutions (21.8%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
DR. August Troendle
Chairman of the Board, President, Chief Executive Officer
Mr. Fred Davenport
Lead Independent Director
Mr. Brian Carley
Independent Director
Ms. Ashley Keating
Independent Director
Dr. Thomas King
Independent Director
Mr. Robert Kraft
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
603 Million
(Quarterly Results - Jun 2025)
Net Profit:
90 Million
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 13,859 Million (Small Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.12

stock-summary
Return on Equity

242.70%

stock-summary
Price to Book

80.41